1. Home
  2. AR vs ABVX Comparison

AR vs ABVX Comparison

Compare AR & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Antero Resources Corporation

AR

Antero Resources Corporation

HOLD

Current Price

$33.41

Market Cap

10.8B

Sector

Energy

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$136.59

Market Cap

11.9B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
AR
ABVX
Founded
2002
2013
Country
United States
France
Employees
N/A
69
Industry
Oil & Gas Production
Sector
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
10.8B
11.9B
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
AR
ABVX
Price
$33.41
$136.59
Analyst Decision
Buy
Buy
Analyst Count
16
13
Target Price
$47.13
$131.31
AVG Volume (30 Days)
4.8M
2.2M
Earning Date
04-29-2026
03-23-2026
Dividend Yield
N/A
N/A
EPS Growth
1027.78
N/A
EPS
1.72
N/A
Revenue
$5,275,823,000.00
N/A
Revenue This Year
$29.74
$52.14
Revenue Next Year
$5.07
$4,132.27
P/E Ratio
$19.75
N/A
Revenue Growth
21.97
N/A
52 Week Low
$29.10
$9.79
52 Week High
$45.75
$148.83

Technical Indicators

Market Signals
Indicator
AR
ABVX
Relative Strength Index (RSI) 41.04 61.06
Support Level $32.85 $106.03
Resistance Level $35.86 $148.41
Average True Range (ATR) 1.02 5.48
MACD -0.04 1.74
Stochastic Oscillator 23.03 80.88

Price Performance

Historical Comparison
AR
ABVX

About AR Antero Resources Corporation

Antero Resources is an exploration and production firm whose operations represent a pure play in the Marcellus Shale, located in northern West Virginia. The company started in 2002 as an E&P focused on the Barnett Shale (Fort Worth, Texas). Antero redefined itself in Appalachia's Marcellus Shale in 2005. In 2012, shortly before Antero's 2013 IPO, Antero Midstream Partners was formed to handle the company's rapidly growing gas volumes. In 2026, the firm narrowed its focus further by selling its Ohio Utica assets and using the proceeds to acquire additional Marcellus acreage from HG Energy. Just over half of its production and earning power is tied to natural gas, with the remainder mostly NGLs, where it holds a leading position, and some crude oil.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.

Share on Social Networks: